ReP USP - Resultado da busca

Artigo de periodico
Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups From 2010 to 2019 a systematic analysis for the global burden of disease study 2019 (2022)
Kocarnik, Jonathan M; Compton, Kelly; Dean, Frances E; Fu, Weijia; Gaw, Brian L; Harvey, James D; Henrikson, Hannah Jacqueline; Lu, Dan; Pennini, Alyssa; Alonso, Nivaldo
Fonte: Jama oncology. Unidade: FM
Assuntos: VIGILÂNCIA SANITÁRIA, NEOPLASIAS, COVID-19, ESTATÍSTICAS VITAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOCARNIK, Jonathan M et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups From 2010 to 2019 a systematic analysis for the global burden of disease study 2019. Jama oncology, v. 8, n. 3, p. 420-444, 2022Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2021.6987. Acesso em: 29 ago. 2024.
APA
Kocarnik, J. M., Compton, K., Dean, F. E., Fu, W., Gaw, B. L., Harvey, J. D., et al. (2022). Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups From 2010 to 2019 a systematic analysis for the global burden of disease study 2019. Jama oncology, 8( 3), 420-444. doi:10.1001/jamaoncol.2021.6987
NLM
Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, Henrikson HJ, Lu D, Pennini A, Alonso N. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups From 2010 to 2019 a systematic analysis for the global burden of disease study 2019 [Internet]. Jama oncology. 2022 ; 8( 3): 420-444.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2021.6987
Vancouver
Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, Henrikson HJ, Lu D, Pennini A, Alonso N. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups From 2010 to 2019 a systematic analysis for the global burden of disease study 2019 [Internet]. Jama oncology. 2022 ; 8( 3): 420-444.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2021.6987
Artigo de periodico
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study (2018)
Fitzmaurice, Christina; Akinyemiju, Tomi F; Lami, Faris Hasan Al; Alam, Tahiya; Alizadeh Navaei, Reza; Allen, Christine; Alsharif, Ubai; Alvis Guzman, Nelson; Amini, Erfan; Anderson, Benjamin O; Benseñor, Isabela M
Fonte: Jama oncology. Nome do evento: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Unidade: FM
Assuntos: NEOPLASIAS, INCIDÊNCIA, MORTALIDADE, SOBREVIDA, REVISÃO SISTEMÁTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FITZMAURICE, Christina et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study. Jama oncology, v. 4, n. 11, p. 1553-1568, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2018.2706. Acesso em: 29 ago. 2024.
APA
Fitzmaurice, C., Akinyemiju, T. F., Lami, F. H. A., Alam, T., Alizadeh Navaei, R., Allen, C., et al. (2018). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study. Jama oncology, 4( 11), 1553-1568. doi:10.1001/jamaoncol.2018.2706
NLM
Fitzmaurice C, Akinyemiju TF, Lami FHA, Alam T, Alizadeh Navaei R, Allen C, Alsharif U, Alvis Guzman N, Amini E, Anderson BO, Benseñor IM. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study [Internet]. Jama oncology. 2018 ; 4( 11): 1553-1568.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2018.2706
Vancouver
Fitzmaurice C, Akinyemiju TF, Lami FHA, Alam T, Alizadeh Navaei R, Allen C, Alsharif U, Alvis Guzman N, Amini E, Anderson BO, Benseñor IM. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study [Internet]. Jama oncology. 2018 ; 4( 11): 1553-1568.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2018.2706
Artigo de periodico
Global burden of multiple myeloma aSystematic analysis for the Global Burden of Disease Study 2016 (2018)
Cowan, Andrew J.; Allen, Christine; Barac, Aleksandra; Basaleem, Huda; Benseñor, Isabela Judith Martins; Curado, Maria Paula; Foreman, Kyle; Gupta, Rahul; Harvey, James; Hosgood, H. Dean
Fonte: Jama oncology. Unidade: FM
Assuntos: MIELOMA MÚLTIPLO, REVISÃO SISTEMÁTICA, DIRETRIZES PARA A PRÁTICA CLÍNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COWAN, Andrew J. et al. Global burden of multiple myeloma aSystematic analysis for the Global Burden of Disease Study 2016. Jama oncology, v. 4, n. 9, p. 1221-1227, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2018.2128. Acesso em: 29 ago. 2024.
APA
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Benseñor, I. J. M., Curado, M. P., et al. (2018). Global burden of multiple myeloma aSystematic analysis for the Global Burden of Disease Study 2016. Jama oncology, 4( 9), 1221-1227. doi:10.1001/jamaoncol.2018.2128
NLM
Cowan AJ, Allen C, Barac A, Basaleem H, Benseñor IJM, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD. Global burden of multiple myeloma aSystematic analysis for the Global Burden of Disease Study 2016 [Internet]. Jama oncology. 2018 ; 4( 9): 1221-1227.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2018.2128
Vancouver
Cowan AJ, Allen C, Barac A, Basaleem H, Benseñor IJM, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD. Global burden of multiple myeloma aSystematic analysis for the Global Burden of Disease Study 2016 [Internet]. Jama oncology. 2018 ; 4( 9): 1221-1227.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2018.2128
Artigo de periodico
Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial (2018)
Royce, Melanie; Hegg, Roberto
Fonte: Jama oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, ANTINEOPLÁSICOS, RECEPTORES HORMONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROYCE, Melanie e HEGG, Roberto. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, v. 4, n. 7, p. 977-984, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2018.0060. Acesso em: 29 ago. 2024.
APA
Royce, M., & Hegg, R. (2018). Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, 4( 7), 977-984. doi:10.1001/jamaoncol.2018.0060
NLM
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060
Vancouver
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060
Artigo de periodico
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015 (2017)
Akinyemiju, Tomi; Benseñor, Isabela Judith Martins
Fonte: Jama oncology. Unidade: FM
Assuntos: HEPATOPATIAS, MORTALIDADE, NEOPLASIAS HEPÁTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AKINYEMIJU, Tomi e BENSEÑOR, Isabela Judith Martins. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015. Jama oncology, v. 3, n. 12, p. 1683-1691, 2017Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2017.3055. Acesso em: 29 ago. 2024.
APA
Akinyemiju, T., & Benseñor, I. J. M. (2017). The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015. Jama oncology, 3( 12), 1683-1691. doi:10.1001/jamaoncol.2017.3055
NLM
Akinyemiju T, Benseñor IJM. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015 [Internet]. Jama oncology. 2017 ; 3( 12): 1683-1691.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2017.3055
Vancouver
Akinyemiju T, Benseñor IJM. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015 [Internet]. Jama oncology. 2017 ; 3( 12): 1683-1691.[citado 2024 ago. 29 ] Available from: https://doi.org/10.1001/jamaoncol.2017.3055

Unidades USP

ReP

Filtros

Autores

Assuntos

Agência de fomento